MIF Variant rs755622 Is Associated with Severe Crohn’s Disease and Better Response to Anti-TNF Adalimumab Therapy

Jezernik, Gregor; Gorenjak, Mario; Potočnik, Uroš

doi:10.3390/genes14020452

Cited by 4 publications

(2 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with the GG allele were shown to have greater disease activity. Similar observations have been made in patients with rheumatoid arthritis and psoriatic arthritis [41]. A new direction of research and the role of genetics in response to biological therapy are bioinformatics analyses of many cohorts [17].…”

Section: Omics Research In Anti-tnf Pharmacogeneticssupporting

confidence: 64%

Apoptosis and inflammatory genes variants in primary non-response to anti-TNF therapy in Crohn’s disease patients

Łykowska‐Szuber

Walczak

Dobrowolska

et al. 2023

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Anti-TNF therapy has indeed revolutionized the treatment of Crohn’s disease, leading to higher rates of response and remission in patients. However, a significant proportion of 20–40% of patients do not respond to the initial therapy, others experience a secondary loss of response with ongoing treatment. Adverse drug reactions also occur in some patients. The effectiveness of anti-TNF treatment may be influenced by genetic variability, including FCGR3A, ADAM17, TNFRSF1A, TNFRSF1B, FAS, FASL, IL1B, CASP9, and MIF genes. In this article, we provide an overview of the current knowledge and findings in the pharmacogenetics of anti-TNF drugs in CD focusing on the aspect of apoptosis and inflammatory genes variants in primary non-response. Pharmacogenetic investigations have been conducted to identify genetic markers that can predict response to anti-TNF therapy. However, large multi-center validation studies and multi-loci algorithms development are required to effectively prognose the treatment effect. The identification of predictive markers of response to anti-TNF therapy can help clinicians make informed decisions about treatment options and minimize adverse drug reactions in patients.

show abstract

Section: Omics Research In Anti-tnf Pharmacogeneticssupporting

confidence: 64%

Apoptosis and inflammatory genes variants in primary non-response to anti-TNF therapy in Crohn’s disease patients

Łykowska‐Szuber

Walczak

Dobrowolska

et al. 2023

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

show abstract

“…Thus, SNPs in this gene could affect the bacterial composition of the gut of patients with IBD and immune recognition. In this context, the presence of rs10210302 correlates in CD with a beneficial response to ADA therapy [61,62]. SNP rs1295686, in the IL-13 gene, is of biological interest given that it is implicated, as a functional enhancer, with the TH2LCRR promoter (T helper type 2 locus control region-associated RNA).…”

Section: Discussionmentioning

confidence: 99%

Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review

Plaza,

Mínguez,

Bastida

et al. 2024

IJMS

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the digestive tract usually characterized by diarrhea, rectal bleeding, and abdominal pain. IBD includes Crohn’s disease and ulcerative colitis as the main entities. IBD is a debilitating condition that can lead to life-threatening complications, involving possible malignancy and surgery. The available therapies aim to achieve long-term remission and prevent disease progression. Biologics are bioengineered therapeutic drugs that mainly target proteins. Although they have revolutionized the treatment of IBD, their potential therapeutic benefits are limited due to large interindividual variability in clinical response in terms of efficacy and toxicity, resulting in high rates of long-term therapeutic failure. It is therefore important to find biomarkers that provide tailor-made treatment strategies that allow for patient stratification to maximize treatment benefits and minimize adverse events. Pharmacogenetics has the potential to optimize biologics selection in IBD by identifying genetic variants, specifically single nucleotide polymorphisms (SNPs), which are the underlying factors associated with an individual’s drug response. This review analyzes the current knowledge of genetic variants associated with biological agent response (infliximab, adalimumab, ustekinumab, and vedolizumab) in IBD. An online literature search in various databases was conducted. After applying the inclusion and exclusion criteria, 28 reports from the 1685 results were employed for the review. The most significant SNPs potentially useful as predictive biomarkers of treatment response are linked to immunity, cytokine production, and immunorecognition.

show abstract

Precision medicine in inflammatory bowel disease

Zeng,

Jiang,

et al. 2023

Precision Clinical Medicine

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is an incurable disease characterized by remission-relapse cycles throughout its course. Both Crohn's disease (CD) and ulcerative colitis (UC), the two main forms of IBD, exhibit tendency to develop complications and substantial heterogeneity in terms of frequency and severity of relapse, thus posing great challenges to the clinical management for IBD. Current treatment strategies are effective in different ways in induction and maintenance therapies for IBD. Recent advances in studies of genetics, pharmacogenetics, proteomics and microbiome provide a strong driving force for identifying molecular markers of prognosis and treatment response, which should help clinicians manage IBD patients more effectively, and then, improve clinical outcomes and reduce treatment costs of patients. In this review, we summarize and discuss precision medicine in IBD, focusing on predictive markers of disease course and treatment response, and monitoring indices during therapeutic drug monitoring.

show abstract

MIF Variant rs755622 Is Associated with Severe Crohn’s Disease and Better Response to Anti-TNF Adalimumab Therapy

Cited by 4 publications

References 47 publications

Apoptosis and inflammatory genes variants in primary non-response to anti-TNF therapy in Crohn’s disease patients

Apoptosis and inflammatory genes variants in primary non-response to anti-TNF therapy in Crohn’s disease patients

Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review

Precision medicine in inflammatory bowel disease

Contact Info

Product

Resources

About